Evidence map›Paper›PMID 26101312›Full record

GuidelineJournal of feline medicine and surgery2015

Feline injection-site sarcoma: ABCD guidelines on prevention and management.

Katrin Hartmann, Michael J Day, Etienne Thiry, Albert Lloret, Tadeusz Frymus, Diane Addie, Corine Boucraut-Baralon, Herman Egberink, Tim Gruffydd-Jones, Marian C Horzinek and 8 more

Open access · greenAbstract readPractice Guideline
In one paragraph

Guideline in Journal of feline medicine and surgery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.

  1. WSAVA Guidelines for the vaccination of dogs and cats.The Journal of small animal practice · 2016
    Guideline
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Expression of αAnimals : an open access journal from MDPI · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 2 countries.

Katrin Hartmann
Michael J Day
Etienne Thiry
Albert Lloret
Tadeusz Frymus
Diane Addie
Corine Boucraut-Baralon
Herman Egberink
Tim Gruffydd-Jones
Marian C Horzinek
Margaret J Hosie
Hans Lutz
Fulvio Marsilio
Maria Grazia Pennisi
Alan D Radford
Uwe Truyen
Karin Möstl
European Advisory Board on Cat Diseases
University of Bristol · GBAt Bristol · GBUniversity of Liège · BE

Funding

Biotechnology and Biological Sciences Research Council BB/D008425/1Medical Research Council G0300387
6 · The paper itself

Abstract

overviewIn cats, the most serious of adverse effects following vaccination is the occurrence of invasive sarcomas (mostly fibrosarcomas): so-called 'feline injection-site sarcomas' (FISSs). These develop at sites of previous vaccination or injection. They have characteristics that are distinct from those of fibrosarcomas in other areas and behave more aggressively. The rate of metastasis ranges from 10-28%. PATHOGENESIS: The pathogenesis of these sarcomas is not yet definitively explained. However, chronic inflammatory reactions are considered the trigger for subsequent malignant transformation. Injections of long-acting drugs (such as glucocorticoids, and others) have been associated with sarcoma formation. Adjuvanted vaccines induce intense local inflammation and seem therefore to be particularly linked to the development of FISS. The risk is lower for modified-live and recombinant vaccines, but no vaccine is risk-free. TREATMENT AND PREVENTION: Aggressive, radical excision is required to avoid tumour recurrence. The prognosis improves if additional radiotherapy and/or immunotherapy (such as recombinant feline IL-2) are used. For prevention, administration of any irritating substance should be avoided. Vaccination should be performed as often as necessary, but as infrequently as possible. Non-adjuvanted, modified-live or recombinant vaccines should be selected in preference to adjuvanted vaccines. Injections should be given at sites at which surgery would likely lead to a complete cure; the interscapular region should generally be avoided. Post-vaccination monitoring should be performed.

Indexed as

AnimalsAnimal WelfareCat DiseasesCatsHousing, AnimalSarcomaSoft Tissue NeoplasmsVaccinationVeterinary Medicine

Identifiers

PMID26101312
PMCPMC11148925
OpenAlexW1879159451

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.